A Phase 1, Dose Escalation, Double Blind, Placebo Controlled Clinical Trial With Controlled Human Malaria Infections (CHMI) to Evaluate Safety, Tolerability, Pharmacokinetics, and Protective Efficacy of an Anti-Malaria Human Monoclonal Antibody, MAM01, in Healthy, Malaria-Naive Adults
Latest Information Update: 25 Feb 2025
At a glance
Most Recent Events
- 29 Oct 2024 Planned primary completion date changed from 1 Mar 2025 to 1 Dec 2024.
- 23 Aug 2023 Status changed from not yet recruiting to recruiting.
- 09 Jun 2023 New trial record